HER3 NSCLC Text Module

CME

Exploring the Clinical Landscape of Novel HER3-Targeted Treatments for Advanced NSCLC

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 06, 2023

Expiration: November 05, 2024

Rebecca S. Heist
Rebecca S. Heist, MD, MPH

Activity

Progress
1
Course Completed

Which of the following is a true statement about potential adverse events (AEs) with patritumab deruxtecan that the healthcare team should understand to develop appropriate strategies to identify and manage associated treatment-related adverse event (TRAE)?